Product Description
Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14871155/)
Mechanisms of Action: ADRA1A Agonist,ADRA2A Agonist,CYP2D6 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Israel | United Kingdom | United States
Approved Indications: Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity
Known Adverse Events: Tachycardia | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Insomnia | Asthenia | Diarrhea | Weight Loss | Urinary Tract Infections | Attention Deficit Disorder with Hyperactivity | Anorexia
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRI108-ADD-600 | P2 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2021-10-15 |
32% |